TMED2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using HLA-DRB1 mouse mAb against Raji (1)cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Raji cells using HLA-DRB1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human tonsil tissues using HLA-DRB1 mouse mAb with DAB staining.    

  
  

TMED2 (Transmembrane emp24 domain-containing protein 2), also known as p24β1 or p25. is a member of the transmembrane emp24 domain-containing protein family. It functions as a cargo receptor in the secretory pathway, facilitating the transport of glycosylphosphatidylinositol (GPI)-anchored proteins and other secretory cargoes from the endoplasmic reticulum (ER) to the Golgi apparatus. TMED2 is a critical component of the p24 protein complex, which plays roles in maintaining ER structure, regulating COPII vesicle formation, and ensuring quality control of secreted proteins.

TMED2 antibodies are essential tools for studying its expression, localization, and molecular interactions. These antibodies are commonly used in techniques such as Western blotting, immunofluorescence, and co-immunoprecipitation to investigate TMED2's involvement in cellular processes like protein trafficking, autophagy, and cell signaling. Research has linked TMED2 dysregulation to diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. For example, elevated TMED2 expression has been observed in certain tumors, where it may promote cell proliferation and metastasis by modulating secretory pathways or extracellular matrix remodeling.

Validated TMED2 antibodies typically target specific epitopes within its N-terminal domain or transmembrane regions. Researchers prioritize antibodies with high specificity, often confirmed via knockout cell lines or siRNA knockdown. Host species (e.g., rabbit, mouse) and clonality (monoclonal/polyclonal) vary depending on experimental needs. Understanding TMED2's role through these antibodies contributes to insights into secretory pathway mechanics and potential therapeutic targeting in disease contexts.